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Abstract 
Objectives: To evaluate the prevalence of sarcopenia in a sample of older, sedentary women 
using criteria from the European Working Group on Sarcopenia in Older People (EWGSOP), the 
International Working Group (IWG), and the Foundation for the National Institutes of Health 
Sarcopenia Project (FNIHSP).  Design: Cross-sectional analysis.  Setting and Participants: 
Community-dwelling women (n = 61) aged 71.9 ± 4.6 years (mean±SD) with a BMI 27.3 ± 6.0 
kg/m2 who by self-report were healthy and did not exercise were recruited and evaluated for 
sarcopenia.  Measurements: Height, weight, grip strength, gait speed, and appendicular lean mass 
(via segmental multi-frequency bioelectrical impedance analysis: SMF-BIA) were measured. 
Prevalence was reported using descriptive statistics and a Fisher’s exact test was used to analyze 
the distribution frequency of sarcopenia classification by different criteria.  Results: In this 
sample 14.8% met EWGSOP criteria, 6.6% met FNIHSP criteria, and 3.3% met IWG criteria. 
There was a borderline significant difference in distribution frequency between EWGSOP and 
IWG classification criteria (p=0.053).  Conclusion: The variation in sarcopenia prevalence 
depending on the diagnostic criteria used is consistent with previous research and there are 
borderline significant differences between classification criteria in this population. These data 
suggest the need for additional examination to determine current cut points for ALM measured 
by SMF-BIA, as well as which established definition of sarcopenia is appropriate for this 
population.  
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Introduction 
 Sarcopenia is the progressive, naturally occurring loss of lean muscle mass that 
accompanies the aging process [1].  Decreases in lean muscle mass have been associated with 
reduced physical function, osteoporosis, and loss of independence [2-4].  Sarcopenia-related 
health care costs for women in 2000 were approximately $7.7 billion, and several recent 
investigations have also found the presence of sarcopenia to increase individual healthcare costs 
in various populations [5-8].  Furthermore, healthcare costs are expected to increase as US 
census population estimates project that by 2050 the amount of US adults over the age of 65 will 
double [9].  The associated healthcare costs coupled with the growing population indicate that 
sarcopenia is a serious public health concern.  Therefore, early detection and intervention 
methods need to be developed in order to alleviate the chronic effects of this condition among 
different populations. 
 The prevalence of sarcopenia has previously been reported in various populations using 
different diagnostic criteria, and has ranged from 1-30% in samples of older community dwelling 
women [10-12].  However, lack of agreement among criteria presents challenges for clinicians 
and researchers attempting to identify sarcopenic individuals.  Recently, three sets of diagnostic 
criteria for sarcopenia have been developed by the European Working Group on Sarcopenia in 
Older People (EWGSOP), the International Working Group (IWG), and the Foundation for the 
National Institutes of Health Sarcopenia Project (FNIHSP)  [13-16].  These criteria include 
measures of lean mass, physical function, and/or muscular strength.  However, these criteria do 
not use consistent variables and cut points for quantifying lean mass and physical functioning, 
and lack overall agreement.  
 Few studies have reported the prevalence of sarcopenia in older community dwelling 
women using these three sets of diagnostic criteria.  However, in 2014 Dam et al. conducted a 
comparison of EWGSOP, IWG, and FNIHSP sarcopenia classification criteria among the cohort 
used to develop the FNIHSP criteria, and found large variations in prevalence estimates 
depending on the classification criteria used [17].  While a strong and thorough investigation, 
participants were not recruited based on their physical activity levels and it is unclear if 
prevalence estimates will vary in a sedentary cohort.  Therefore, the purpose of this study was to 
report and compare the prevalence of sarcopenia using EWGSOP, IWG, and FNIHSP criteria in 
a sample of older, sedentary, community dwelling Rhode Island women.   
Methods 
Study Design and Participants 
 To evaluate sarcopenia prevalence, a cross-sectional analysis was performed among a 
sample of older, community dwelling Rhode Island women who were recruited for an 
intervention trial through talks and posters at local community and senior centers, and by word of 
mouth.  Initial screening was conducted via telephone interview to include women who were 
postmenopausal, aged 65-84 years, and by self report were not involved in a regular exercise 
program or participation in physical activities outside of activities of daily living.  Reasons for 
study exclusion included failure to provide informed consent, inability to speak and read English, 
diagnosed cognitive impairment, and the inability to safely engage in mild to moderate intensity 
exercise.  Participants with recent major joint, vascular, abdominal or thoracic surgery were 
excluded.  Participants who self-reported clinically diagnosed cardiovascular disease, pulmonary 
disease, or with an implanted pacemaker or defibrillator were excluded.  Also, participants with 
uncontrolled diabetes, hypertension, or anemia were excluded.  Any participant who reported 
medication changes within 3 weeks or changes to lipid lowering medication within 6 months 
were excluded.  Trained study staff members performed all components of data collection.  
 Eligible participants read and signed informed consent and also completed a teach-back 
process, which required participants to explain learned information on the consent form back to a 
study staff member to ensure participants understood all aspects of the informed consent form.  
Anthropometric data were then collected followed by tests to evaluate participants’ body 
composition, muscular strength, and gait speed.  All aspects of this study took place in the 
Kinesiology Department on the campus of the University of Rhode Island, Kingston, Rhode 
Island, USA. This study was approved by the Institutional Review Board of the University of 
Rhode Island.  
Anthropometrics 
 Height was measured without shoes to the nearest 0.1 cm using a Seca wall mounted 
stadiometer and body weight was measured without shoes to the nearest 0.1 kg using a Seca 
balance beam scale (Seca, Chino, CA).  Height and weight were measured in duplicate and 
averages were used to calculate body mass index (BMI).  
Body Composition 
 Whole and regional body composition was measured via segmental multi-frequency 
bioelectrical impedance analysis (SMF-BIA) using an Inbody 570 Biospace device (Biospace 
Co, Ltd, Korea) according to the manufacturer’s guidelines.  Participants were asked to be fully 
hydrated, fasted for > 4 hours, and to void their bladder prior to the test.  Appendicular lean mass 
(ALM) was calculated as the sum of lean mass in both arms and legs and expressed in kg.  In 
accordance with EWGSOP and IWG criteria, ALM was adjusted for height expressed as meters 
squared, while according to FNIHSP criteria ALM was adjusted for BMI.  
Muscular Strength 
 Isometric handgrip strength has been documented as a safe and effective method of 
predicting total body strength and future disability[18, 19].  Muscular strength was measured via 
grip strength from a seated position using a Jamar Hydraulic Hand Dynamometer (J.A. Preston, 
Corp., Jackson, MS).  Participants completed two trials per hand and the highest overall score 
from either hand (kg) was used for sarcopenia classification.  
Gait Speed 
 Gait speed is an easily assessed measure that has been shown to be predictive of future 
disability [20].  To evaluate gait speed, participants were instructed to walk a 4-meter distance at 
their normal walking pace [21].  Two trials were completed and the fastest time (meters/sec) was 
used for sarcopenia classification. 
Sarcopenia Classification  
 Sarcopenia was classified using EWGSOP, IWG, and FNIHSP criteria published 
previously [13-15, 17].  These criteria are the most prominent among the literature; incorporate 
symptoms associated with sarcopenia, and have been shown to identify clinically relevant, 
sarcopenia-induced deficiencies in strength and physical function.  The EWGSOP criteria utilize 
established stages of sarcopenia classification (presarcopenia, sarcopenia, severe sarcopenia), 
with low ALM/ht2 (< 5.67 kg/m2) and the presence of low gait speed (≤ 0.8 m/s) or low grip 
strength (< 20 kg) required to be classified as sarcopenic.  A severe sarcopenia classification 
requires low ALM/ht2, gait speed, and grip strength.  Presarcopenia was defined as having low 
ALM/ht2 only.  The IWG criteria utilizes a “yes/no” classification method, requiring individuals 
to be below established cut points of both gait speed (< 1.0 m/s) and ALM/ht2 (< 5.67 kg/m2) to 
be considered sarcopenic.  The FNIHSP also uses established stages of sarcopenia classification: 
“weak with low lean mass and weak and slow with low lean mass.”  In contrast to EWGSOP and 
IWG criteria, the FNIHSP uses ALM/BMI (< 0.512) to quantify lean mass, while also using 
differing cut points of gait speed (< 0.8 m/s) and grip strength (< 16 kg).  A “weak with low lean 
mass” classification required participants to be below cut points of ALM/BMI and grip strength, 
while a “weak and slow with low lean mass” required participants to be below cut points of 
ALM/BMI, grips strength, and gait speed.  Participant data were collected and applied to these 
individual sets of criteria to determine the prevalence of sarcopenia within this sample.  
 
Statistical Analysis 
   Descriptive statistics were used to report the baseline characteristics (means ± standard 
deviation) of the cohort and sarcopenia prevalence.  A Fisher’s exact test was used to determine 
the distribution frequency of sarcopenia classification among the different sets of classification 
criteria.  Significance was set at p ≤ 0.05. Statistical analyses were performed using SAS 
statistical software (SAS Institute Inc., Cary, NC). 
Results 
 A total of 61 Caucasian women aged 71.9 ± 4.6 years were included in the analyses.  
Baseline characteristics of the population are presented in Table 1.  Thirteen participants were 
considered sarcopenic.  As shown in Table 1, nine (14.8%) participants were considered 
sarcopenic by EWGSOP criteria, four (6.6%) were considered weak with low ALM/BMI by 
FNIHSP criteria, and two (3.3%) participants were considered sarcopenic by IWG criteria.  
Sarcopenia prevalence for all criteria combined was 21.3% with no participant counted more 
than once.  The two participants considered sarcopenic by IWG criteria were also considered 
sarcopenic by EWGSOP criteria.  No other participants were considered sarcopenic by two or 
more sets of criteria.  Additionally, no participants were considered pre-sarcopenic or severely 
sarcopenic by EWGSOP criteria or weak and slow with low lean mass by FNIHSP criteria.  A 
Fisher’s exact test showed borderline significant differences in distribution frequency between 
EWGSOP and IWG classification criteria (p = 0.053).  No significant differences were found 
between other sets of classification criteria.  
Discussion 
 These data indicate the large variation in sarcopenia prevalence depending on the 
classification criteria used.  Within this sample, sarcopenia prevalence ranged from 3.3% to 
14.8% with borderline significant differences in distribution frequency between EWGSOP and 
IWG criteria.  This wide variation in prevalence is consistent with the findings of Cruz-Jentoft et 
al., who through systematic review found sarcopenia prevalence in community dwelling women 
ranged from 1-30% when estimated using EWGSOP criteria [12].  However, the authors 
expressed difficulty in comparing results of many studies due to inconsistent methodologies used 
in studies included in their review.  
 In comparison, Patel et al. applied EWGSOP criteria to data from the Hertfordshire 
Cohort Study (HCS), which included 1,022 older women [22].  While the baseline characteristics 
of this cohort closely resemble those of our sample, the study reported a 7.9% sarcopenia 
prevalence compared to our result of 19.7% using EWGSOP criteria.  While those differences 
may be attributed to sample size, it may also be due to differences in grip strength.  The HCS 
reported a mean grip strength of 26.3 kg while our results show a mean grip strength of only 17.6 
kg, which is below the EWGSOP cut point for weakness in older women.  This is consistent with 
the findings of Beaudart et al. who found grip strength criteria to largely influence sarcopenia 
prevalence [23]. 
 While there are considerably more data regarding sarcopenia prevalence using EWGSOP 
criteria, few studies have utilized IWG and/or FNIHSP criteria.  However, Dam et al. in 2014 
applied FNIHSP, IWG, and EWGSOP criteria to data collected from 2,950 older women through 
9 different studies.  That analysis found 2.3% of women to be weak and slow by FNIHSP 
criteria, 11.8% were sarcopenic by IWG criteria, and 13.3% were sarcopenic by EWGSOP 
criteria [17].  Those researchers also noted that participants considered to have low lean mass by 
the ALM/BMI method were heavier with larger BMIs compared to those with low ALM/ht2.  
Our findings agree with those results, as every participant in our study who fell below the 
ALM/BMI cut-point had a BMI > 30 kg/m2.  These results suggest that the FNIHSP criteria may 
be more effective at identifying sarcopenia in obese populations, while EWGSOP and IWG 
criteria may be more appropriate in non-obese populations.  While our prevalence results vary 
with the findings of Dam et al. [17], possibly due to differences in sample size, it is evident that 
EWGSOP criteria consistently classify greater percentages of older women as sarcopenic when 
compared to FNIHSP and IWG criteria, and ALM adjusted for BMI may be the more effective 
method of identifying sarcopenia in obese, older women.  
 Reasons for variations in prevalence have recently been investigated by Masanés et al., 
who found that modification of EWGSOP lean mass cut points greatly varied sarcopenia 
prevalence, while modifying grip strength and gait speed cut points elicited little change in 
prevalence [24].  However, those findings suggest that a large percentage of this population may 
have already been below the cut points for grip strength, as a combination of low ALM and 
weakness is required for a sarcopenia diagnosis by EWGSOP criteria.  
 Consequently, our data show that the majority of participants considered sarcopenic by 
EWGSOP criteria had low ALM and weakness (n = 9), while no participants had low ALM 
accompanied with low gait speed.  This also explains our low prevalence reported when using 
IWG criteria, which does not include grip strength, and has a more liberal gait speed cut point.  
This suggests that inclusion of grip strength in sarcopenia diagnostic criteria may result in 
relatively higher prevalence estimates, and further screening for hand ailments (i.e. arthritis) may 
be necessary for accurate sarcopenia classification.  
 While the EWGSOP criteria are most prevalent within the literature, it does not take fat 
or body mass into consideration and may fail to classify those with sarcopenic obesity, as shown 
in our results [2].  Therefore, researchers may benefit from utilizing multiple sets of criteria 
when estimating sarcopenia prevalence as anthropometric, body composition, and physical 
functioning data are needed to use any of the aforementioned criteria.  Moreover, the FNIHSP 
criteria may be ideal for the older female population as following menopause women typically 
experience increases in fat mass, which could prevent diagnosis by EWGSOP or IWG criteria 
[25].  Our results underscore the discrepancies between different sets of sarcopenia classification 
criteria and therefore, inclusion of multiple sets of criteria may simplify the comparison of 
results and aid in determining population appropriate diagnostic criteria.   
 A small sample size, and a low number of participants who met classification criteria 
limited this study.  A further limitation was the use of SMF-BIA to assess ALM rather than dual-
energy x-ray absorptiometry (DXA).  However, SMF-BIA has been found to be agreeable with 
DXA for measuring ALM in women, and BIA specific ALM/ht2 cut points presented by the 
EWGSOP were developed using prediction equations not applicable to the InBody 570 device 
[26, 27].  Despite limitations, this study is novel in that EWGSOP, IWG, and FNIHSP criteria 
were all applied to the same sample of older, sedentary women from the same community.  This 
allowed for the comparison of criteria without the need to adjust for sex, ethnicity, or activity 
levels.  This study demonstrates the variability and limitations of current sarcopenia 
classification criteria, especially in obese individuals, and indicates the need for future research 
to develop current, criteria-appropriate cut-points for the measurement of ALM by SMF-BIA in 
this population to complement these findings.  
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